Vedanta Biosciences, a Cambridge, Massachusetts-based developer of oral Live Biotherapeutic Products using defined bacterial consortia, has raised $60 million in funding. The round includes $40 million in equity led by AMR Action Fund and BNP Paribas Asset Management Alts plus $20 million from an existing BARDA contract. The company develops standardized, powdered bacterial consortia for gastrointestinal diseases, starting with VE303 for prevention of recurrent Clostridioides difficile infection.
Microbiome Field Moves Past Donor Stool
The timing aligns with a shift away from donor-derived fecal microbiota transplants. Seres Therapeutics received FDA approval for VOWST in 2023 but relies on purified spores from donor stool. Rebiotix/Ferring gained approval for REBYOTA in 2022 with an enema formulation also based on donor material. Finch Therapeutics, which pursued a similar FMT route, filed for Chapter 11 in 2026 after raising $184 million. Vedanta's defined consortia approach avoids donor variability entirely.
Recurrent C. Diff Carries High Recurrence Risk
Recurrent C. difficile infection affects up to 175,000 patients annually in the US and causes approximately 20,000 deaths each year. Patients face repeated cycles of infection after antibiotic treatment, with limited options beyond further antibiotics that worsen dysbiosis. Current approved microbiome products still depend on donor stool, introducing manufacturing and regulatory variability that Vedanta's clonal cell bank method sidesteps.
Defined Consortia Enable Consistent Manufacturing
Vedanta's VE303 combines eight rationally selected strains produced from cell banks in powdered oral capsules. Phase 2 data showed 13.8 percent recurrence versus 45.5 percent on placebo. The ongoing Phase 3 RESTORATiVE303 trial has passed an interim analysis with the data monitoring committee recommending continuation, and enrollment has exceeded 80 percent across 150-plus sites in roughly 20 countries. A second program, VE707, targets Gram-negative antimicrobial-resistant infections and received a $3.9 million CARB-X award.
BARDA and AMR Investors Signal Strategic Backing
The $60 million package extends runway through the expected 2027 Phase 3 readout. AMR Action Fund and BNP Paribas Asset Management Alts led the equity portion, while BARDA provided additional non-dilutive support under an existing contract. The appointments of Dr. Manos Perros as Executive Chairman and Andrew Davis to the board bring regulatory and transaction experience ahead of potential commercialization.
Market Projects Strong Growth Through 2030
Grand View Research projects the microbiome therapeutics market will expand from $255.1 million in 2026 to $1.07 billion in 2030 at a 35.3 percent CAGR. Multiple approvals have validated the category, yet most approved or advanced programs still rely on donor material. Vedanta's manufacturing facility and defined-consortia platform position it for the next wave of standardized live biotherapeutics.
Phase 3 Data Expected in First Half of 2027
With enrollment over 80 percent and an interim analysis passed, the company is positioned to complete the pivotal trial in the second half of 2026. Topline efficacy data are anticipated in the first half of 2027, intended to support a biologics license application.